Eton Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary
Revenue more than doubled in 2025 following the successful launch of three cornerstone products: Incrolix, Galzyn, and Kinduvi. Management attributes ...
Revenue more than doubled in 2025 following the successful launch of three cornerstone products: Incrolix, Galzyn, and Kinduvi. Management attributes ...
Copyright © 2022-2024
All Rights Reserved
See articles for original source and related links to external sites.
Copyright © 2022-2024
All Rights Reserved
See articles for original source and related links to external sites.